N = 13 | Related to nivolumab alone | Related to cabiralizumab alone | Related to sotigalimab alone | Related to all | ||||
---|---|---|---|---|---|---|---|---|
Treatment-Related Adverse Events | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 | Grade 1–2 | Grade ≥ 3 |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Chills | - | - | - | - | 8 (62) | 0 (0) | - | - |
Fatigue & weakness | 1 (8) | 0 (0) | - | - | - | - | 8 (62) | 0 (0) |
Periorbital edema | - | - | 6 (46) | 0 (0) | - | - | - | - |
Alanine aminotransferase increase | - | - | - | - | - | - | 7 (54) | 1 (8) |
Aspartate aminotransferase increase | - | - | - | - | - | - | 3 (23) | 5 (38) |
Creatine phosphokinase increase | - | - | 2 (15) | 4 (31) | - | - | - | - |
Fever | - | - | - | - | 4 (31) | 0 (0) | - | - |
Nausea/vomiting | - | - | - | - | 3 (23) | 0 (0) | - | - |
Diarrhea | 1 (8) | 0 (0) | - | - | - | - | - | - |
Headache | - | - | - | - | 3 (23) | 0 (0) | - | - |
Rash—maculopapular | - | - | - | - | - | - | 3 (23) | 0 (0) |
Hypothyroidism | 2 (15) | 0 (0) | - | - | - | - | - | - |
Creatinine increase | - | - | - | - | - | - | 2 (15) | 0 (0) |
Pruritis | - | - | - | - | - | - | 1 (8) | 0 (0) |
Myalgia | - | - | - | - | 1 (8) | 0 (0) | - | - |
Lipase increase | 1 (8) | 0 (0) | - | - | - | - | - | - |
Thrush | 1 (8) | 0 (0) | - | - | - | - | - | - |
Hypotension | - | - | - | - | 1 (8) | 0 (0) | - | - |
Hypoglycemia | - | - | - | - | - | - | 0 (0) | 1 (8) |
Flushing | - | - | - | - | 1 (8) | 0 (0) | - | - |
Edema in limbs | - | - | 1 (8) | 0 (0) | - | - | - | - |
Bilirubin increase | - | - | - | - | - | - | 0 (0) | 1 (8) |
Sinus tachycardia | - | - | - | - | 1 (8) | 0 (0) | - | - |
Anemia | - | - | - | - | - | - | 1 (8) | 0 (0) |
Platelet count decrease | - | - | - | - | - | - | 1 (8)* | 0 (0) |